Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Colorcon
Boehringer Ingelheim
McKinsey

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Pa-824


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Pa-824?

Pa-824 is an investigational drug.

There have been 25 clinical trials for Pa-824. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2015.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and Tuberculosis, Multidrug-Resistant. The leading clinical trial sponsors are Global Alliance for TB Drug Development, Wits Health Consortium (Pty) Ltd, and London School of Hygiene and Tropical Medicine.

There are twenty-five US patents protecting this investigational drug and one hundred and eighty-seven international patents.

Recent Clinical Trials for Pa-824
TitleSponsorPhase
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)Global Alliance for TB Drug DevelopmentPhase 2
Economic Evaluation of New MDR TB RegimensClinical HIV Reserach Unit, Wits Health ConsortiumPhase 2/Phase 3
Economic Evaluation of New MDR TB RegimensLiverpool School of Tropical MedicinePhase 2/Phase 3

See all Pa-824 clinical trials

Clinical Trial Summary for Pa-824

Top disease conditions for Pa-824
Top clinical trial sponsors for Pa-824

See all Pa-824 clinical trials

US Patents for Pa-824

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pa-824 ⤷  Sign up for a Free Trial Multi-drug therapies for tuberculosis treatment The Regents of the University of California (Oakland, CA) ⤷  Sign up for a Free Trial
Pa-824 ⤷  Sign up for a Free Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign up for a Free Trial
Pa-824 ⤷  Sign up for a Free Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
Pa-824 ⤷  Sign up for a Free Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pa-824

Drugname Country Document Number Estimated Expiration Related US Patent
Pa-824 China CN107249691 2034-11-03 ⤷  Sign up for a Free Trial
Pa-824 European Patent Office EP3215225 2034-11-03 ⤷  Sign up for a Free Trial
Pa-824 Japan JP2017533220 2034-11-03 ⤷  Sign up for a Free Trial
Pa-824 World Intellectual Property Organization (WIPO) WO2016073524 2034-11-03 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Colorcon
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.